Summary of Pacira BioSciences, Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: Achieved $726 million for the full year 2025, with Q4 revenue of $155.8 million for EXPAREL, up from $147.7 million in Q4 2024.

Gross Margin: Non-GAAP gross margin improved to 80% in Q4 2025, up from 79% in Q4 2024, driven by enhanced manufacturing efficiencies.

R&D and SG&A Expenses: Non-GAAP R&D expenses rose to $34.4 million in Q4 from $22 million in 2024. Non-GAAP SG&A expenses increased to $91.9 million from $70.6 million, impacted by unexpected business development costs and litigation.

Cash Position: Exited Q4 with $238 million in cash and investments, supporting ongoing growth initiatives.

2Strategic Updates and Business Highlights

Five-by-30 Strategy: Focused on helping 3 million patients annually by 2030, with current patient reach at 2.5 million.

Partnerships: Secured a partnership with LG Chem for EXPAREL in Asia Pacific, expected to generate revenue starting in 2027. The partnership with J&J MedTech is anticipated to enhance ZILRETTA's market reach.

Pipeline Development: Advancements in pipeline programs including PCRX-201 and PCRX-2002, with key clinical milestones expected in 2026.

NO PAIN Initiative: Expanded access to EXPAREL, now covering 102 million lives outside the surgical bundle, facilitating a shift in opioid prescribing patterns.

3Forward Guidance and Outlook

2026 Revenue Guidance: Projected total revenue of $745 million to $770 million, with EXPAREL sales expected between $600 million and $620 million.

Gross Margins: Anticipated non-GAAP gross margins of 77% to 79% for 2026, with expectations for steady annual increases.

Expense Projections: Non-GAAP R&D expenses projected at $105 million to $115 million, and SG&A expenses at $320 million to $340 million.

4Bad News, Challenges, or Points of Concern

Market Conditions: Anticipated challenges in the first quarter of 2026 due to adverse weather impacting elective procedures, which could affect sales.

ZILRETTA Performance: Sales for ZILRETTA were flat in 2025, attributed to a focus on EXPAREL and restructuring sales forces, which may continue to pose challenges in establishing growth.

Increased Expenses: Rising R&D and SG&A expenses may pressure profitability if not managed effectively.

5Notable Q&A Insights

Efficacy Trends for PCRX-201: The focus of the upcoming Phase II study is on safety, with secondary endpoints assessing pain and function. The results will be contextualized against existing data from the IGOR registry.

Factors Influencing Revenue Guidance: The guidance reflects a conservative approach due to potential headwinds in the elective procedure market, with room for upside as market dynamics evolve.

Adoption vs. Reimbursement: The company is seeing positive sentiment around EXPAREL, but barriers to adoption remain, primarily related to clinical adoption rather than reimbursement issues. Overall, Pacira BioSciences is positioned for growth with a solid revenue outlook and strategic initiatives, though it faces challenges in market conditions and expense management.